STOCK TITAN

Amylyx Pharmaceuticals Inc - AMLX STOCK NEWS

Welcome to our dedicated news page for Amylyx Pharmaceuticals (Ticker: AMLX), a resource for investors and traders seeking the latest updates and insights on Amylyx Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amylyx Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amylyx Pharmaceuticals's position in the market.

Rhea-AI Summary
Amylyx Pharmaceuticals provides an update on the review of its Marketing Authorisation Application for AMX0035 for the treatment of ALS by the CHMP of the EMA. The CHMP is trending toward a negative opinion, but Amylyx plans to request a formal re-examination if a negative opinion is issued. The MAA is based on data from the CENTAUR clinical trial, which showed significant benefits in function and survival. The CHMP is expected to adopt a formal opinion in June.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.18%
Tags
none
-
Rhea-AI Summary
Amylyx Pharmaceuticals reports Q1 2023 product revenue of $71.4 million and progress in commercial launches of RELYVRIO and ALBRIOZA for ALS treatment. Regulatory review ongoing in the EU. Expansion of pipeline with Phase 2 HELIOS study and planned Phase 3 study in progressive supranuclear palsy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.99%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.4%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
conferences
Amylyx Pharmaceuticals Inc

Nasdaq:AMLX

AMLX Rankings

AMLX Stock Data

136.24M
50.94M
14.24%
104.79%
8.86%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Cambridge

About AMLX

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.